Asthma

Asthma – Medical Student Study Guide

Definition

Asthma is a chronic inflammatory disorder of the airways characterized by variable and recurring symptoms, reversible airflow obstruction, and bronchial hyperresponsiveness. It results from complex interactions between genetic predisposition and environmental exposures, leading to episodic wheeze, breathlessness, chest tightness, and cough.

Epidemiology

Asthma is one of the most common chronic diseases worldwide and a leading cause of morbidity in children and young adults. It affects an estimated 11–14% of children globally and contributes substantially to school absenteeism, disturbed sleep, and healthcare utilization, including emergency visits and hospitalizations.^{[4](https://pubmed.ncbi.nlm.nih.gov/41394393/)}

Prevalence varies by country, urbanization, and socioeconomic status. Pediatric asthma is particularly impactful in low-income and environmentally burdened communities, where exposure to air pollution, allergens, and psychosocial stressors is higher and access to optimal care is reduced.^{[7](https://europepmc.org/article/MED/41693517)}

Pathophysiology

Asthma pathophysiology involves chronic airway inflammation, structural changes (airway remodeling), and increased airway hyperresponsiveness.

• Airway inflammation: Typically driven by type 2 (Th2)-mediated immune responses with involvement of eosinophils, mast cells, type 2 innate lymphoid cells, and cytokines such as IL-4, IL-5, and IL-13. This leads to mucosal edema, mucus hypersecretion, and narrowing of the airway lumen.
• Bronchial hyperresponsiveness: Airways exhibit exaggerated constrictive responses to a variety of stimuli (allergens, cold air, exercise, irritants), resulting in episodic bronchospasm and variable airflow obstruction.
• Airway remodeling: Chronic inflammation can cause smooth muscle hypertrophy, subepithelial fibrosis, goblet cell hyperplasia, and thickening of the basement membrane, contributing over time to more fixed airflow limitation and reduced reversibility.
• Triggers: Common triggers include aeroallergens (dust mites, pollens, molds, animals), viral respiratory infections, exercise, cold air, tobacco smoke, indoor and outdoor pollutants, occupational exposures, medications (e.g., aspirin/NSAIDs, beta-blockers), and strong emotions or stress.

There is increasing recognition that social and environmental stressors (e.g., neighborhood violence, housing instability, environmental injustice) interact with traditional triggers to worsen asthma control and outcomes, especially in children in vulnerable communities.^{[7](https://europepmc.org/article/MED/41693517)}

Clinical Presentation

Asthma typically presents with a constellation of respiratory symptoms that are variable in intensity and frequency.

• Key symptoms:
  • Episodic wheeze (classically expiratory, polyphonic)
  • Dyspnea and breathlessness, especially at night or early morning
  • Chest tightness or pressure
  • Cough, often dry or with minimal sputum; can be predominant ("cough-variant asthma")
• Symptom pattern:
  • Symptoms that vary over time and intensity
  • Worsening with exercise, viral infections, allergen exposure, weather changes, laughter, or irritants (smoke, perfumes)
  • Nighttime and early morning worsening is typical
• Physical examination:
  • Wheezing on auscultation, especially on expiration
  • Prolonged expiratory phase
  • Use of accessory muscles, tachypnea, tachycardia during exacerbations
  • Severe attack: "silent chest" (ominous), inability to speak full sentences, pulsus paradoxus, agitation or drowsiness indicating impending respiratory failure
• Associated conditions:
  • Atopic diseases: allergic rhinitis, atopic dermatitis, food allergies
  • Family history of asthma or atopy

Diagnosis

The diagnosis of asthma is clinical, supported by objective demonstration of variable airflow limitation and exclusion of alternative diagnoses. In medical exams, emphasize the combination of compatible symptoms plus reversible obstruction on spirometry.

Diagnostic Evaluation

• History and physical exam:
  • Recurrent episodes of wheeze, cough, dyspnea, chest tightness
  • Symptom variability and triggers
  • Personal or family history of atopy
  • Impact on sleep, activity, and school/work attendance (in children, frequent absenteeism and ER visits are red flags for poor control).^{[4](https://pubmed.ncbi.nlm.nih.gov/41394393/)}
• Spirometry (age ≥5–6 years):
  • Obstructive pattern: reduced FEV1 and FEV1/FVC ratio below lower limit of normal
  • Reversibility: increase in FEV1 ≥12% and ≥200 mL from baseline after inhaled short-acting bronchodilator supports asthma diagnosis
  • Normal spirometry does not exclude asthma due to variability; repeat testing may be needed when symptomatic.
• Peak expiratory flow (PEF):
  • Useful for monitoring variability and control
  • Diurnal variability >10–13% suggests asthma
• Bronchoprovocation tests:
  • Methacholine or exercise challenge may be used when spirometry is normal but suspicion is high
  • Airway hyperresponsiveness supports the diagnosis
• Allergy testing:
  • Skin prick or specific IgE testing helps identify sensitizing allergens for targeted avoidance or immunotherapy
• Imaging:
  • Chest X-ray usually normal; used mainly to rule out alternative diagnoses or complications (e.g., pneumonia, pneumothorax)

Assessment of Severity and Control

Clinical practice guidelines (GINA, NHLBI) emphasize distinguishing initial severity (mild, moderate, severe) from ongoing control (well-controlled, partly controlled, uncontrolled). Severity is based on symptom frequency, night awakenings, reliever use, activity limitation, lung function, and exacerbation history. Control is reassessed regularly and guides stepwise adjustment of therapy.

Management

Asthma management combines pharmacologic therapy, trigger control, patient (and caregiver) education, and regular follow-up. Modern approaches emphasize anti-inflammatory therapy for all patients with symptoms, discouraging SABA-only regimens due to exacerbation risk.

General Principles

• Goals of therapy:
  • Achieve good symptom control (minimal daytime symptoms, no nocturnal symptoms, normal activity)
  • Prevent exacerbations and minimize need for oral corticosteroids or emergency care
  • Maintain near-normal lung function and prevent fixed airflow limitation
  • Minimize adverse effects of medications
• Education and self-management:
  • Teach inhaler technique, adherence, and use of spacers
  • Provide a written asthma action plan with green/yellow/red zones based on symptoms and PEF
  • Educate on trigger avoidance: tobacco smoke, allergens, indoor/outdoor pollutants
  • In schools, ensure staff preparedness with individualized action plans and access to rescue medications; inadequate preparedness is linked to poorer outcomes.^{[6](https://europepmc.org/article/MED/41606536)}
• Environmental and psychosocial factors:
  • Address housing quality, mold, pests, and environmental exposures
  • Integrate community-level resilience and support strategies in high-burden areas to improve pediatric asthma outcomes.^{[7](https://europepmc.org/article/MED/41693517)}

Pharmacologic Management (Stepwise Approach)

Asthma therapy is typically organized into treatment steps based on symptom frequency, exacerbation risk, and control. Steps are adjusted up or down (“stepwise approach”) depending on control. Therapeutic options include:

• Reliever (rescue) medications:
  • Short-acting β₂-agonists (SABAs): e.g., albuterol. Rapid bronchodilation for acute symptoms and pre-exercise prophylaxis.
  • Low-dose ICS–formoterol as needed: In many contemporary guidelines, as-needed low-dose ICS–formoterol is preferred over SABA-only regimens in adults and adolescents because it concurrently treats bronchospasm and underlying inflammation and reduces severe exacerbations.
• Controller (maintenance) medications:
  • Inhaled corticosteroids (ICS): First-line anti-inflammatory therapy for persistent asthma at low, medium, or high doses, depending on severity.
  • ICS–LABA combinations: For moderate to severe asthma not controlled on low-dose ICS alone. Formoterol-containing combinations can also serve as maintenance and reliever therapy (SMART).
  • Leukotriene receptor antagonists (LTRAs): e.g., montelukast. Alternative or add-on therapy, especially in allergic asthma or exercise-induced bronchoconstriction.
  • Long-acting muscarinic antagonists (LAMAs): e.g., tiotropium as add-on in selected patients with persistent symptoms or exacerbations.
  • Biologic therapies: For severe type 2 asthma (e.g., omalizumab, mepolizumab, benralizumab, dupilumab) based on phenotype and biomarkers.

Single Maintenance and Reliever Therapy (SMART)

SMART uses a single inhaler containing ICS–formoterol for both daily maintenance and as-needed relief. This strategy simplifies regimens and has strong evidence for reducing exacerbations compared with traditional fixed-dose ICS/LABA plus SABA reliever, particularly in children and adolescents, though implementation barriers exist (e.g., recognition in schools and logistics of inhaler use).^{[2](https://pubmed.ncbi.nlm.nih.gov/41532159/)} For exams, know that ICS–formoterol SMART is preferred at certain steps in many guidelines for patients with moderate to severe asthma and frequent exacerbations.

Non-Pharmacologic Measures

• Smoking cessation and avoidance of secondhand smoke
• Weight optimization in obese patients
• Treatment of comorbidities: rhinosinusitis, GERD, OSA, anxiety/depression
• Vaccinations: influenza, pneumococcal as appropriate
• Allergen avoidance measures where clearly linked to symptoms (e.g., encasing bedding, reducing dust mites, pet removal if sensitized and symptomatic)

Acute Exacerbations

Asthma exacerbations are episodes of progressive worsening of symptoms and lung function. Prompt recognition and treatment reduce risk of respiratory failure and death.

• Assessment:
  • Severity: mild, moderate, severe, life-threatening based on symptoms, vital signs, PEF/FEV1, and mental status
  • Look for red flags: inability to speak in full sentences, drowsiness, confusion, silent chest, cyanosis
• Treatment (typical ED/acute care approach):
  • High-dose inhaled SABA (e.g., repeated albuterol via MDI + spacer or nebulizer)
  • Short course of systemic corticosteroids (e.g., oral prednisone or IV methylprednisolone)
  • Adjuncts: inhaled ipratropium, oxygen to maintain adequate saturation, IV magnesium sulfate in severe cases
  • Monitor clinical status and PEF/FEV1; escalate support as needed
• Discharge and prevention:
  • Optimize long-term controller therapy, reinforce action plan
  • Review inhaler technique and adherence
  • Arrange follow-up and address environmental and psychosocial factors

Asthma in Children and School Settings

Childhood asthma significantly affects school attendance, academic performance, and quality of life, contributing disproportionately to missed school days and sleep disruption.^{[4](https://pubmed.ncbi.nlm.nih.gov/41394393/)} Effective school-based management requires collaboration between healthcare providers, families, and school health staff, with clear action plans, access to medications, and appropriate training for recognition and treatment of exacerbations.^{[6](https://europepmc.org/article/MED/41606536)} Emerging models emphasize integrating community resilience and addressing environmental and psychosocial stressors to improve long-term outcomes in high-risk communities.^{[7](https://europepmc.org/article/MED/41693517)}

Key Clinical Pearls and Exam Tips

• Variable, reversible obstruction is the core diagnostic concept: symptoms plus spirometric reversibility after bronchodilator.
• Nighttime and early-morning symptoms and worsening with exercise, allergens, or cold air strongly suggest asthma over other causes of wheeze.
• Normal spirometry does not exclude asthma; consider repeat testing or bronchoprovocation when suspicion is high.
• ICS are the cornerstone of controller therapy; SABA-only regimens are outdated and associated with increased exacerbation risk.
• SMART (ICS–formoterol) is an evidence-based strategy that uses a single inhaler for maintenance and relief and reduces exacerbations, especially in children and adolescents with persistent asthma.^{[2](https://pubmed.ncbi.nlm.nih.gov/41532159/)}
• In children, frequent school absenteeism, nocturnal symptoms, and repeated ER visits indicate poor control and high future risk, prompting reassessment of therapy and environment.^{[4](https://pubmed.ncbi.nlm.nih.gov/41394393/)}
• Severe exacerbation red flags: silent chest, altered mental status, exhaustion, bradycardia, or rising PaCO₂ on blood gas indicate impending respiratory failure.
• Always review inhaler technique and adherence before escalating to higher treatment steps or advanced biologics.
• Consider alternative diagnoses in atypical cases: COPD, vocal cord dysfunction, heart failure, bronchiectasis, foreign body, or chronic infection.

Summary

Asthma is a chronic, heterogeneous airway disease characterized by variable respiratory symptoms and reversible airflow limitation. For medical students, mastery of its pathophysiology, clinical features, diagnostic criteria, and evidence-based management – including ICS-based controller therapy and strategies like SMART – is essential. Understanding the broader context of environmental exposures, school and community factors, and health system support is increasingly important for comprehensive, patient-centered asthma care.^{[2](https://pubmed.ncbi.nlm.nih.gov/41532159/)[4](https://pubmed.ncbi.nlm.nih.gov/41394393/)[7](https://europepmc.org/article/MED/41693517)}